CONFERENCE PRESENTATIONS

Conference Presentations

Replicor personnel and collaborators attend and often present at all the major international scientific conferences where HBV or HDV is discussed. Selected presentations can be downloaded below.

Conference Location Abstract/Poster
27.7.2024Singapore Hepatology Conference / Science of HBV CureSingaporeUpdate on NAPs:
Understanding biochemical interactions
and pharmacokinetics
Oral presentation
27.7.2024Singapore Hepatology Conference / Science of HBV CureSingaporeThe role of NAPs in therapy of
Chronic HDV infection
Oral presentation
7.6.2024European Association for the Study of the Liver 2024 Annual MeetingMilan, ItalyCompassionate use of REP 2165-Mg in chronic HBV/HDV patients with
progressive liver disease and failure to previous pegIFN therapy
Poster FRI-443
6.6.2024European Association for the Study of the Liver 2024 Annual MeetingMilan, ItalySafety and efficacy of REP 2139-Mg in
hepatitis D patients with advanced liver disease:
an international compassionate use program
Oral presentation OS-034
5.6.2024European Association for the Study of the Liver 2024 Annual MeetingMilan, ItalyAntiviral efficacy of REP 2139-Mg and effects on HVPG in HDV/HBV coinfected patients
with cirrhosis and portal hypertension non-responding to previous bulevirtide treatment
Poster WED-383
10.11.2023AASLD 2023Boston, USASafety and efficacy of REP 2139-Mg in association with TDF
in chronic hepatitis delta patients with decompensated cirrhosis.
Poster presentation
10.11.2023AASLD 2023Boston, USASafety and efficacy of REP 2139-Mg-based therapy in French patients with prior failure to pegIFN and or bulevirtide.Poster presentation
10.11.2023AASLD 2023Boston, USASafety and Efficacy of REP 2139-Mg-based therapy in Austrian patients with HBV / HDV compensated cirrhosis with prior failure to bulevirtide.Poster presentation
10.11.2023AAASLD 2023Boston, USAREP 2139 targets the hepatitis delta virus (HDV) ribonucleoprotein (RNP)
and exerts a direct antiviral effect on HDV replication.
Poster presentation
10.11.2023AASLD 2023Boston, USAPangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B surface antigen.Poster presentation
30.09.2023Canadian Association of the Liver HBV Single Topic ConferenceCalgary, CanadaCompassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection:
a first Canadian experience
Poster presentation
23.09.2023International Meeting on the Molecular Biology of HBVKobe, JapanREP 2139 has a direct antiviral effect on HDV replication.Oral presentation
23.09.2023International Meeting on the Molecular Biology of HBVKobe, JapanIdentification of DNAJB12 as a chaperone involved in the secretion of HBsAg and a target of the NAPs REP 2139.Oral presentation
21.06.2023Hepatitis Delta International Network
(EASL 2023)
Vienna AustriaNAPs for treatment of chronic hepatitis D: a tale from real life?Oral presentation
24.06.2023EASL 2023Vienna, AustriaRescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-MgPoster SAT-169
24.06.2023EASL 2023Vienna, AustriaSafety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosisPoster SAT-183
07.05.2023Digestive Disease Weekly 2023Chicago, USARescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-MgOral presentation
08.05.2023Digestive Disease Weekly 2023Chicago, USARescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-MgPoster of Distinction
28.04.2023Global Hepatitis Summit 2023Paris FranceExtended follow-up in the REP 301 and REP 401 studies demonstrates durable clinical benefit from NAP therapyLate breaking oral presentation O105
28.04.2023Global Hepatitis Summit 2023Paris FranceRescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-MgOral presentation
28.04.2023Global Hepatitis Summit 2023Paris FranceSafety and efficacy of REP 2139-Mg in association with TDF in patients with chronic hepatitis delta and decompensated cirrhosisOral presentation
15.02.2023APASL 2023Taipei, TaiwanSafety and efficacy of REP 2139-Mg in association with TDF in patients with chronic hepatitis delta and decompensated cirrhosisPoster OC-29
(Award of excellence)
18.02.2023APASL 2023Taipei, TaiwanRescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-MgOral presentation OC-28
(Awarded best oral presentation)
1.12.2022World Antiviral ConferenceSan Diego, USAHBsAg Loss and Transaminase Flares: Therapeutic Implications for Functional Cure of HBVOral Presentation
04.11.2022AASLD 2022Washington DC, USACompassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infectionPoster Presentation
04.11.2022AASLD 2022Washington DC, USAIdentification of the Hsp40 chaperone DNAJB12 in the functional mechanism of the nucleic acid polymer REP 2139Poster Presentation
04.11.2022AASLD 2022Washington DC, USADefining the mechanism of action of the Hsp40 chaperones DNAJB12 and DNAJB14 in the assembly and secretion of Hepatitis B subviral particlesPoster Presentation
07.10.2022DeltaCure 2022Milan, ItalyRescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-MgPoster Presentation
07.10.2022DeltaCure 2022Milan, ItalyA biochemical basis for the hepatoprotective effects of REP 2139 during host mediated transaminase flaresPoster Presentation
07.10.2022DeltaCure 2022Milan, ItalySustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV / HDV co-infectionPoster Presentation
20.09.20222022 International HBV meetingParis, FranceIdentification of the Hsp40 chaperone DNAJB12 in the functional mechanism of the antiviral nucleic
acid polymer REP 2139 and establishment of its mechanism of action in the secretion of HBsAg.
Poster Presentation
19.09.20222022 International HBV meetingParis, FranceUnderstanding mechanisms and effects of oligonucleotide-based drugs in chronic HBV infectionPoster Presentation
19.09.20222022 International HBV meetingParis, FranceSustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV / HDV co-infectionPoster Presentation
19.09.20222022 International HBV meetingParis, FranceCompassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infectionPoster Presentation
22.06.202221st meeting of the Hepatitis Delta International NetworkLondon, UKCompassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV coinfectionOral Presentation
31.05.20222022 Science of HBV CureSingaporeAchieving clearance of subviral particles with NAPs:
A critical milestone for HBsAg loss and functional cure
Oral Presentation
25.04.20222nd Annual Chronic HBV Drug Development CongressBoston, USAWorkshop A:
Agents in development targeting HBsAg
Oral Presentation
25.04.20222nd Annual Chronic HBV Drug Development CongressBoston, USAWorkshop B:
Clinical progress in targeting cccDNA
Oral Presentation
27.04.20222nd Annual Chronic HBV Drug Development CongressBoston, USAHBsAg loss and transaminase flares:
Critical milestones for functional cure.
Oral Presentation
20.04.2022World Vaccine CongressWashington DC, USAHBsAg Loss and Transaminase Flares:
Therapeutic Implications for Functional Cure of HBV
Oral Presentation
7.12.2021HepDart 2021Cabo San Lucas, MexicoOligonucleotide-based strategies for targeting HBsAg:
Understanding mechanisms and effects
Oral Presentation
7.12.2021HepDart 2021Cabo San Lucas, MexicoPh dependent target interaction of NAPsPoster 1
7.12.2021HepDart 2021Cabo San Lucas, MexicoCompassionate use of subcutaneously administered REP 2139-Mg in HBV / HDV infectionPoster 7
2.12.2021World Antiviral ConferenceSan DiegoHBsAg Loss and Transaminase Flares:
Therapeutic Implications for Functional Cure of HBV
Oral Presentation
15.11.2021AASLD 2021 (TLMdX)OnlineTransition of REP 2139-Mg to subcutaneous administrationLate Breaking Poster LP-14
15.11.2021AASLD 2021 (TLMdX)OnlineHBsAg response during NAP therapy predicts functional curePresidential poster of distinction 840
15.11.2021AASLD 2021 (TLMdX)OnlineAntiviral responses during TDF monotherapy in the REP 401 studyPoster 805
15.11.2021AASLD 2021 (TLMdX)OnlinePh dependent target interaction of NAPsPoster 836
13.10.2021Science of HBV Cure
(Singapore Hepatitis Conference)
OnlineNucleic acid polymers: Biochemistry, molecular mechanism and application in the achievement of functional cureOral presentation
28.09.2021International HBV Meeting 2021OnlinePh-dependent interaction of NAPs with the HSP40 chaperone DNAJB12Poster presentation
18.06.2021Global Hepatitis Summit / ISVHLD 2021OnlineExperimental endpoint analysis during NAP-based therapyOral presentation
23.06.2021EASL ILC 2021OnlineHBV kinetics during NAP-based therapyPoster 1837
5.05.2021Chronic Hepatitis B drug development (Hanson Wade)OnlineHBsAg, Subviral Particles and Their Clearance in Establishing
Functional Cure of Chronic HBV Infection
Oral presentation
13.11.2020TLMdX (AASLD 2020)OnlineNAP target
identification
Late breaking
poster LP42
13.11.2020TLMdX (AASLD 2020)OnlineCompassionate use
of NAPs in cirrhotic
HBV / HDV coinfection
Poster 0827
13.11.2020TLMdX (AASLD 2020)OnlineHBsAg isoform
analysis in REP 301
and REP 401 studies
Poster 0819
13.11.2020TLMdX (AASLD 2020)OnlineIn vitro evaluation of
NAPs in the absence
of virion assembly
Poster 0818
27.08.2020 Digital ILC EASL 2020 Online Experimental virologic endpoints in the REP 301/301-LTF and REP 401 studies Late breaking poster
16.7.2020 Blumberg Institute HBV Seminar Series Webinar Understanding HBsAg and Subviral Particles: Key players in chronic HBV infection, Key targets in achieving functional cure of HBV Slide deck
16.7.2020 Blumberg Institute HBV Seminar Series Webinar Understanding HBsAg and Subviral Particles: Key players in chronic HBV infection, Key targets in achieving functional cure of HBV Seminar video
10.12.2019 HEPDART 2019 Kauai, USA Beneficial effects of transaminase flares and predicting virologic control and functional cure during NAP therapy Replicor REP 401 301 Flares versus outcome poster O3 HEPDART 2019 FINAL
10.12.2019 HEPDART 2019 Kauai, USA Final follow-up data from REP 401 (HBV) and REP 301-LTF (HBV / HDV) Replicor REP 401 301-LTF Complete follow-up poster P15 HEPDART 2019 FINAL
9.12.2019 HEPDART 2019 Kauai, USA Beneficial effects of transaminase flares and predicting virologic control and functional cure during NAP therapy (ORAL) Replicor flares vs outcomes O3 Hepdart 2019 FINAL
09.12.2019 HEPDART 2019 Kauai, USA Detailed data presentation of transfection artifacts with NAPs in vitro Assessing the in vitro activity of NAPs in HBV
09.12.2019 HEPDART 2019 Kauai, USA Accurately assessing in vitro activity of NAPs Poster Accurately assessing in vitro activity of NAPs Poster
09.11.2019 HDIN meeting at AASLD 2019 Boston, Canada REP 301-LTF 3.5 year follow-up REP 301-LTF HDIN AASLD 2019 FINAL
08.11.2019 AASLD 2019 Boston, USA REP 301-LTF 3.5 year follow-up REP 301-LTF 3.5 year follow-up AASLD 2019 FINAL
06.11.2019 2019 HBV Cure Workshop Toronto, Canada Clinical and mechanistic update on NAPs Replicor REP 301-LTF REP 401 flares update HBV Cure 2019 FINAL
04.10.2019 2019 International HBV meeting Melbourne, Australia REP 401 study final results and predicting functional cure of HBV. REP 401 final results HBV meeting 2019 Oral
03.10.2019 2019 International HBV meeting Melbourne, Australia Transaminase flares in the absence of HBsAg during REP 2139 + pegIFN therapy predict functional cure of HBV. Replicor HBV meeting 2019 flares vs outcome Poster 242
03.10.2019 2019 International HBV meeting Melbourne, Australia In vitro effects of REP 2139 on the HBV lifecycle. INRS Replicor HBV meeting 2019 in vitro Poster 241
08.06.2019 Science of HBV Cure Singapore REP 401 study final results and predicting functional cure of HBV REP 401 final results SHC 2019
12.04.2019 EASL ILC 2019 Vienna, Austria Safety and Tolerability of Transaminase flares during therapy of HBV REP 301 401 Transaminases EASL 2019 Poster FRI-211
12.04.2019 EASL ILC 2019 Vienna, Austria REP 401 trial + MOA update (Poster) REP 401 EASL 2019 Poster FRI-210
10.04.2019 HDIN Meeting at EASL ILC 2019 Vienna, Austria Safety and efficacy of transaminase flares in HBV and HDV. REP 301 401 transaminase flares HDIN EASL 2019
08.03.2019 EASL / AASLD HBV Endpoints 2019 London, UK REP 401 trial + MOA update (Oral) REP 401 EASL AASLD Endpoints 2019 Oral OP-02 FINAL
08.03.2019 EASL / AASLD HBV Endpoints 2019 London, UK REP 401 trial + MOA update (Poster) REP 401 EASL AASLD Endpoints 2019 Poster OP-02 FINAL
08.03.2019 EASL / AASLD HBV Endpoints 2019 London, UK Safety and Tolerability of Transaminase flares during therapy of HBV REP 301 401 Transaminases EASL AASLD Endpoints 2019 Poster P03-01 FINAL
23.02.2019 APASL 2019 Manila, Philippines Achieving functional cure with REP 2139 REP 401 APASL 2019 FINAL
10.11.2018 Hepatitis Delta International Network Meeting (AASLD 2018) San Francisco, USA REP 301-LTF update
REP 2139-Mg transition to SC
HDIN AASLD 2018
9.11.2018 AASLD 2018 San Francisco, USA Achieving functional cure with REP 2139 REP 401 AASLD 2018
7.11.2018 HBV Cure Workshop 2018 Toronto, Canada REP 401 study interim follow-up update HBV Cure Workshop 2018
6.10.2018 2018 HBV International Meeting Taormina, Italy Achieving functional cure with REP 2139 REP 2139 clinical HBV INT 2018
5.10.2018 2018 HBV International Meeting Taormina, Italy REP 2139 mechanism of action in vitro REP 2139 vs HBsAg HBV INT 2018
4.10.2018 2018 HBV International Meeting Taormina, Italy Apolipoproteins in HBsAg secretion in vitro Apos vs HBsAg HBV INT 2018
25.09.2018 Discovery on Target 2018: Targeting HBV Boston, USA Achieving functional cure with REP 2139 CHT Targeting HBV 2018
15.06.2018 Global Hepatitis Summit 2018

(16th International Symposium of Viral Hepatitis and Liver Disease)
Toronto, Canada Updated follow-up analysis in the REP 401 protocol. GHS 2018 presentation
09.06.2018 Science of HBV Cure

(Singapore Hepatitis Conference)
Singapore, Singapore Achieving functional control of HBV and HDV infection with REP 2139-based combination therapy Combination therapy presentation
08.06.2018 Science of HBV Cure

(Singapore Hepatitis Conference)
Singapore, Singapore REP 2139 mechanistic insights and effects in monotherapy Monotherapy presentation
13.04.2018 EASL ILC 2018 Paris, France Modelling viral kinetics during REP 2139-Ca monotherapy Poster FRI-324
13.04.2018 EASL ILC 2018 Paris, France Updated follow-up data in the REP 301-LTF study (HBV/HDV). Poster FRI-326
13.04.2018 EASL ILC 2018 Paris, France Updated follow-ip data in the REP 401 study (HBV) Poster FRI-343
07.12.2017 HEPDART 2017 Kona, HI, U.S.A. REP 401 Interim follow-up update Presentation O-19
21.10.2017 AASLD 2017 Washington, DC, U.S.A REP 401 Interim follow-up update Poster LB-24
21.10.2017 AASLD 2017 Washington, DC, U.S.A Update on NAP mechanism of action in HBV Poster 957
21.10.2017 AASLD 2017 Washington, DC, U.S.A Update on NAP mechanism of action in HDV Poster 942
25.09.2017 CHT Discovery on Target:Targeting HBV Boston, U.S.A. Targeting HBsAg secretion with NAPs: Drug development update Presentation
05.09.2017 HBV International Meeting 2017 Washington DC, U.S.A. Modelling post-entry effects of NAPs against HBV infection in vitro. Poster P-146
05.09.2017 HBV International Meeting 2017 Washington DC, U.S.A. Activity of NAPs against HDV in vivo Poster P-144
05.09.2017 HBV International Meeting 2017 Washington DC, U.S.A. NAPs interact with small and large hepatitis delta antigen Poster P-145
05.09.2017 HBV International Meeting 2017 Washington DC, U.S.A. HBsAg Quasispecies evolution in the REP 102 trial. Poster P-127
05.09.2017 HBV International Meeting 2017 Washington DC, U.S.A. Mathematical modelling of viral dynamics in the REP 102 protocol. Poster P-148
05.09.2017 HBV International Meeting 2017 Washington DC, U.S.A. Clinical NAP Summary (critical role for HBsAg suppression in achieving functional cure. Poster P-147
07.09.2017 HBV International Meeting 2017 Satellite Symposium Washington DC, U.S.A. Clinical NAP Summary (critical role for HBsAg suppression in achieving functional cure. Presentation O-198.
20.04.2017 HDIN meeting (EASL 2017) Amsterdam, The Netherlands REP 301 / 301-LTF update HDIN (EASL 2017) Presentation HDIN (EASL 2017)
20.04.2017 EASL 2017 Amsterdam, The Netherlands REP 301 / 301-LTF update LBP-507 Poster LBP-507
20.04.2017 EASL 2017 Amsterdam, The Netherlands REP 401 update EASL 2017 THU-154 Poster THU-154
20.04.2017 EASL 2017 Amsterdam, The Netherlands REP 102 HBsAg deep sequencing EASL 2017 THU-155 Poster THU-155
20.04.2017 EASL 2017 Amsterdam, The Netherlands NAP post-entry activity modelling in vitro EASL 2017 THU-156 Poster THU-156
20.04.2017 EASL 2017 Amsterdam, The Netherlands Modeling HBsAg and HDV DNA kinetics EASL 2017 THU-173 Poster THU-173
18.02.2017 APASL 2017 Shanghai, China Update on Safety and Efficacy in the REP 401 protocol APASL 2017 oral presentation
15.11.2016 AASLD 2016 Boston, U.S.A. Preliminary efficacy and safety from the REP 401 trial: REP 2139 / REP 2165 + peg-IFN + TDF in HBeAg negative HBV infection AASLD 2016 oral presentation
14.11.2016 AASLD 2016 Boston, U.S.A. Follow-up results from the REP 301 trial: REP 2139 + peg-IFN in HBV / HDV co-infection AASLD 2016 REP 301 poster
22.9.2016 HBV 2016 Seoul, Korea Effects of nucleic acid polymers on hepatitis B virus entry in HepaRG cells and primary human hepatocytes HBV 2016 HBV Poster
22.9.2016 HBV 2016 Seoul, Korea Inhibition of Hepatitis Delta Virus infection by Nucleic Acid Polymers – an in vitro analysis – HDV 2016 HDV Poster
4.15.2016 EASL 2016 Barcelona, Spain Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection Poster FRI-105 EASL 2016
4.14.2016 EASL 2016 Barcelona, Spain Nucleic acid-based polymers effective against hepatitis B virus infection in patients do not harbour immune stimulatory properties in primary isolated blood or liver cells Poster THU-204 EASL 2016
4.14.2016 EASL 2016 Barcelona, Spain Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogues against chronic hepatitis B Poster THU-177 EASL 2016
2.22.2016 APASL 2016 Tokyo, Japan On-treatment reduction of HBsAg and HDV RNA with REP 2139-Ca and pegylated interferon alpha 2a in Caucasian Patients with chronic HBV / HDV co-infection Replicor REP 301 APASL 2016 O-130web
2.22.2016 APASL 2016 Tokyo, Japan Potentiation of antiviral effect in vivo against HBV by combined therapy with REP 2139-Ca and nucleos(t)ide analogues Replicor APASL 2016 Combo NAPS In vivo P-0329
8.12.2015 HEP DART 2015 Wailea, Hawaii On-Treatment Reduction of HBsAg and HDV RNA with REP 2139-Ca and Pegylated Interferon alpha 2a in Caucasian Patients with Chronic HBV/HDV REP301 HEPDART 2015 FINAL (Abstract 60)
8.12.2015 HEP DART 2015 Wailea, Hawaii Combination Therapy with the Nucleic Acid Polymer REP 2139-Ca and Nucleos(t)ide Analogues Improves Antiviral Responses Against Hepatitis B

In Vivo
COMBO NAPS HEPDART 2015 FINAL (Abstract 114)
11.15.2015 AASLD 2015 San Francisco Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV / HDV co-infection in Caucasian patients. Replicor REP 301 AASLD 2015 (Abstract 31)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Antiviral effects of nucleic acid polymers on Hepatitis B virus infection in vitro (P-217) Replicor NAPs in vitro (HBV) HBV 2015 (P-217)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Immunostimulatory properties of nucleic acid polymers (P-221) Replicor NAPs Immunostimulation HBV 2015 (P-221)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Benefit of interferon-free, nucleic acid polymer-based combination therapy for chronic Hepatitis B (P-238) Replicor NAPs + NUCs in vivo HBV 2015 (P-238)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Modifications of nucleic acid polymers decrease liver accumulation without affecting antiviral activity (P-239) Replicor Diff NAPs in vivo HBV 2015 (P-239)
10.7.2015 Int. Mol. Biol. HBV 2015 Bad Nauheim Activity of various nucleic acid polymers in blocking hepatitis delta virus entry in vitro (P-242) Replicor NAPs in vitro (HDV) HBV 2015 (P-242)
6.25.2015 ISVHLD 2015 Berlin REP 2139 monotherapy and combination therapy with pegylated interferon:

Safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV / HDV co-infection (O-09)
ISVHLD 2015 Presentation
4.25.2015 EASL ILC 2015 Vienna Significant reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian patients with HBV / HDV co-infection (LO2) EASL 2015 Presentation
4.25.2015 EASL ILC 2015 Vienna HBV RNA analysis in Asian patients treated with REP 2139-Ca (O114) EASL 2015 Presentation
4.25.2015 EASL ILC 2015 Vienna Serum cytokine response in Asian HBV infected patients treated with REP 2139-Ca (P0659) EASL 2015 Poster
4.25.2015 EASL ILC 2015 Vienna Pre-clinical assessment of various NAPs in HBV infection (P0542) EASL 2015 Poster
4.25.2015 EASL ILC 2015 Vienna Activity of NAPs against HDV infection in vitro (LP26) EASL 2015 Poster
4.23.2015 EASL ILC 2015 Vienna Activity of NAPs against HBV infection in vitro (P0556) EASL 2015 Poster
4.10.2015 Lancet Hepatitis Summit 2015 Shanghai REP 2055 / REP 2139-Ca Asian Clinical data update Lancet Poster
10.12.2014 OTS 2014 San Diego REP 2055 / REP 2139-Ca Asian Clinical data update OTS Presentation
5.12.2013 TIDES 2013 Boston REP 2055 / REP 2139-Ca Efficacy and Safety TIDES Presentation
4.26.2013 EASL 2013 Amsterdam REP 2139-Ca Asian Clinical data EASL Poster